Fermion is a clinical-stage AI-enabled drug discovery company with a specialized focus on small molecules:

Fermion Drug Studio AI platform offers a standardized, integrated solution for drug discovery.

Fermion focuses on developing differentiated BIC/FIC products that target novel targets in neurology and autoimmune diseases. With an emphasis on improved target selectivity and tissue targeting, we have demonstrated success by establishing more than ten small molecule drug programs.

Our History

Fermion was founded in 2018 by serial entrepreneur and Sun Yat-Sen University alumni Dr. Deco Deng. Through the continued development of our AI platform and pipeline, Fermion has successfully conducted four rounds of funding. Efficient marketing strategies in conjunction with proven results have allowed us to continually attract and engage with various institutional investors to maintain our trajectory of rapid growth.